Post by c2crusher on Aug 6, 2018 20:48:11 GMT
HitGen Extends and Expands Research Collaboration and License Agreement with MSD to Build and Screen Novel DNA-Encoded Libraries
www.hitgen.com/enxiandao/index.php?s=/Home/Article/detail/id/457.html
Chengdu, China, July 30, 2018 HitGen Ltd. is pleased to announce that the company has extended and expanded its agreement with MSD, known as Merck & Co., Inc, Kenilworth NJ., USA into a multi-year research collaboration and license agreement to build and screen novel DNA-encoded libraries (DELs) in order to discover potential unique small molecule assets to be used in drug discovery and development. Through the collaboration, HitGen and MSD scientists will apply HitGen’s advanced technology platform and research capabilities in the design, synthesis, and screening of multiple proprietary DELs for MSD’s drug discovery efforts. In addition, HitGen will interrogate their own DELs, consisting of hundreds of billions of compounds, against a selected number of MSD’s therapeutic targets. Novel lead compounds from the HitGen DELs will be licensed exclusively to MSD for further research and development. MSD will support the research at HitGen.
“We are delighted to announce the expansion and extension of this collaboration with MSD. Our scientists will continue to work closely together to design and build proprietary DELs to support the discovery of a new generation of medicines to address unmet clinical challenges. This collaboration reflects HitGen’s capabilities, expertise, and flexibility to develop business models to meet the needs of our collaboration partners, and provides insight into the success of our initial target-based collaboration” said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen.
“This expanded collaboration builds upon the strong relationship we have developed with researchers at HitGen as we apply the DEL technology across our portfolio” said Dr. Emma Parmee, Vice President, Global Discovery Chemistry, MSD.
Crusher
www.hitgen.com/enxiandao/index.php?s=/Home/Article/detail/id/457.html
Chengdu, China, July 30, 2018 HitGen Ltd. is pleased to announce that the company has extended and expanded its agreement with MSD, known as Merck & Co., Inc, Kenilworth NJ., USA into a multi-year research collaboration and license agreement to build and screen novel DNA-encoded libraries (DELs) in order to discover potential unique small molecule assets to be used in drug discovery and development. Through the collaboration, HitGen and MSD scientists will apply HitGen’s advanced technology platform and research capabilities in the design, synthesis, and screening of multiple proprietary DELs for MSD’s drug discovery efforts. In addition, HitGen will interrogate their own DELs, consisting of hundreds of billions of compounds, against a selected number of MSD’s therapeutic targets. Novel lead compounds from the HitGen DELs will be licensed exclusively to MSD for further research and development. MSD will support the research at HitGen.
“We are delighted to announce the expansion and extension of this collaboration with MSD. Our scientists will continue to work closely together to design and build proprietary DELs to support the discovery of a new generation of medicines to address unmet clinical challenges. This collaboration reflects HitGen’s capabilities, expertise, and flexibility to develop business models to meet the needs of our collaboration partners, and provides insight into the success of our initial target-based collaboration” said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen.
“This expanded collaboration builds upon the strong relationship we have developed with researchers at HitGen as we apply the DEL technology across our portfolio” said Dr. Emma Parmee, Vice President, Global Discovery Chemistry, MSD.
Crusher